Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $44.13 Million |
|---|---|
| Enterprise Value | $60.78 Million |
| Earnings per Share | $-0.02 |
| Beta | 1.72 |
| Outstanding Shares | 1,068,588,418 |
| P/E Ratio | -4.31 |
|---|---|
| PEG | 5.54 |
| Price to Sales | - |
| Price to Book Ratio | -0.04 |
| Enterprise Value to Revenue | 0.6 |
| Enterprise Value to EBIT | -3.28 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.41 |
| Debt to Equity | -1.46 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Shield Therapeutics plc operates as a specialized pharmaceutical firm, dedicated to developing and bringing to market advanced clinical therapies that address significant unfulfilled medical requirements. Its flagship product, Accrufer/F...